ERCC1/XPF is a DNA endonuclease with variable expression in primary tumor specimens， and has been investigated as a predictive biomarker for efficacy of platinum-based chemotherapy. The failure of clinical trials utilizing ERCC1 expression to predict response to platinum-based chemotherapy suggests additional mechanisms underlying the basic biology of ERCC1 in the response to interstrand crosslinks (ICLs) remain unknown. We aimed to characterize a panel of ERCC1 knockout (Δ) cell lines， where we identified a synthetic viable phenotype in response to ICLs with ERCC1 deficiency.
ERCC1/XPF is a DNA endonuclease with variable expression in primary tumor specimens， and has been investigated as a predictive biomarker for efficacy of platinum-based chemotherapy. The failure of clinical trials utilizing ERCC1 expression to predict response to platinum-based chemotherapy suggests additional mechanisms underlying the basic biology of ERCC1 in the response to interstrand crosslinks (ICLs) remain unknown. We aimed to characterize a panel of ERCC1 knockout (Δ) cell lines， where we identified a synthetic viable phenotype in response to ICLs with ERCC1 deficiency.
